San Diego-based mostly Viking Therapeutics marked itself as a significant competitor within the weight loss drug market in February just after revealing promising data from the mid-phase demo of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when presented for a weekly injection As well as in March